Z-0224-2023Class II

ORISE Gel Submucosal Lifting Agent--Indicated for use in gastrointestinal endoscopic procedures for...

Name: Z-0224-2023 ORISE Gel Submucosal Lifting Agent--Indicated for use in gastrointestinal endoscopic procedures for...
Creator: Boston Scientific Corporation
Published: 2022-10-10
License: https://open.fda.gov/license/

Boston Scientific Corporation / initiated 2022-10-10 / Open, Classified

FDA source

Boston Scientific Corporation began a recall of ORISE Gel Submucosal Lifting Agent--Indicated for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers or... on 2022-10-10. FDA classified it as Class II and gives the reason as "***Update12/13/22***:Product removal due to higher incidence of adverse events of foreign body reactions*** Potential outcomes associated with foreign body reaction to remnant ORlSE Gel post procedure. Foreign body...". As of 2026-09-10, the recall status on record is Open, Classified.

Recall record

Recall number: Z-0224-2023
Classification: Class II
Status: Open, Classified
Initiated: 2022-10-10
Posted: 2022-11-11
Recalling firm: Boston Scientific Corporation
Product: ORISE Gel Submucosal Lifting Agent--Indicated for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare or other suitable endoscopic device Packaged as follows: UPN: (1)Twin Pack Box 1 M00519200 (2)Twin Pack Box 10 M00519201 (3)Single Pack Box 1 M00519220 (4)Single Pack Box 10 M00519221
Product code: PLL Submucosal Injection Agent
Reason for recall: ***Update12/13/22***:Product removal due to higher incidence of adverse events of foreign body reactions*** Potential outcomes associated with foreign body reaction to remnant ORlSE Gel post procedure. Foreign body reaction which presented as mass formations from remnant ORlSE Gel post-procedure, prompting surgical intervention
FDA root cause: Under Investigation by firm
Action: ***UPDATE 12/13/22** Boston Scientific issued Urgent Medical Device Product Removal Immediate Action Required Orise" Gel Submucosal Lifting Agent via Federal Express Priority Overnight mail on December 14, 2022, (as a Follow-Up To The Previous Product Advisory Dated October 10, 2022). Letter states reason for recall (Product Removal), health risk and action to take: Use and distribution of any remaining unused ORISE Gel Submucosal Lifting Agent products affected by this removal should cease immediately. For patients already treated with ORISE Gel, should the user identify submucosal distortions or mass formations in follow-up endoscopy, endoscopic ultrasound, imaging, or surgery, Boston Scientific recommends taking into account prior ORISE Gel use. Review pathology reports from the prior procedure to help determine the most appropriate course of action. Depending on the pathology present during the initial use of ORISE Gel, and whether it included conditions such as adenoma, high-grade dysplasia, or malignancy, a user may need to do nothing, repeat surveillance, repeat a biopsy, perform further mucosal resection, or plan surgical intervention to rule out any residual lesion. For each patient treated with ORISE Gel, Boston Scientific recommends appending their medical record with a copy of this letter to maintain awareness of this topic. If you identify any product from the affected lots within your inventory, please segregate the product immediately and return it to Boston Scientific in accordance with the enclosed Removal Instructions. If you are a distributor, please note that the depth of this removal is to the end user level and this notification should be forwarded to your customers. If you are a facility that has sent products to another hospital or facility within your network, please ensure that this notification is forwarded to them. Your local Sales Representative can answer any questions that you may have regarding this notification. _________________
Quantity in commerce: 402,968 Total
Distribution: Worldwide Distribution: US (Nationwide) and (Foreign) countries of: Algeria Argentina Argentina Australia Austria Bahrain Belgium Brazil Canada Chile Colombia Costa Rica Cyprus Czech Republic Denmark Ecuador Egypt Finland France Germany Great Britain Greece Hong Kong Hungary Iceland Iraq Ireland Israel Italy Jordan Kuwait Latvia Lebanon Lithuania Luxembourg Mexico Netherlands New Zealand Norway Oman Palestine Panama Per¿ Poland Portugal Romania Russian Fed. Saudi Arabia Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Tunisia Unit.Arab Emir. Zimbabwe
Product codes and lots: GTIN Number : (1) 08714729974567 (2) 08714729974574 (3) 08714729993834 (4) 08714729993841 All batches

Enforcement reports

One row per recalled product line

FDA enforcement reports joined to recall event Z-0224-2023
Recall number	Class	Status	Voluntary or mandated	Report date	Classified
Z-0224-2023	Class II	Ongoing	Voluntary: Firm initiated	2022-11-16	2022-11-10
Z-0225-2023	Class II	Ongoing	Voluntary: Firm initiated	2022-11-16	2022-11-10
Z-0226-2023	Class II	Ongoing	Voluntary: Firm initiated	2022-11-16	2022-11-10

Product code PLL

K180068Class IIORISE GelBoston Scientific / cleared 2018-09-28

MDM coverage of this record lists here, newest first.

About this record

Sourced from the FDA device recall database and the FDA enforcement reports, both ingested from openFDA. The recall record supplies the product, the reason and the product code; the enforcement report supplies the classification. The two datasets are exported by FDA on different days, and the date above is the older of the two, so nothing on this page is newer than it says.

MDM adds the root cause tag, derived from FDA’s own root cause text, and the cross-links to the product code, the clearances named on the record and MDM coverage. Where a recall has not been joined to an enforcement report, no classification is shown.

Data as of 2026-09-30, the FDA export date for this dataset. Page last changed 2026-09-05. View this recall on fda.gov (opens on fda.gov)